Skip to content

Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00705094
Enrollment
30
Registered
2008-06-25
Start date
2008-09-30
Completion date
2012-07-31
Last updated
2014-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-seminomatous, Seminoma, Testicular Cancer

Keywords

cardiovascular risk factors, cardiac function, VO2peak, Chemotherapy

Brief summary

For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular cancer appear to be at higher risk for developing heart disease (heart attack or heart failure), especially if they received chemotherapy. Since these studies were done many years after men received treatment, there was no way to know if other factors contributed to the health problems they experienced. This study is being done because it would be helpful to study heart function and cardiovascular disease risk factors of men who have been diagnosed with testicular cancer, before and after they receive chemotherapy treatment compared to men who receive treatment with surgery alone.

Detailed description

The aim of this pilot study is to examine global and regional LV systolic and diastolic function, cardiac output, cardiac reserve, VO2peak and CVD risk profile in males recently diagnosed with testicular cancer treated with surgery alone or surgery and chemotherapy.

Interventions

None listed

Sponsors

AHS Cancer Control Alberta
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* surgery and surveillance * surgery and multi-cycle chemotherapy * both good and intermediate prognosis seminoma and non-seminomatous germ cell testicular tumors * Karnofsky performance index \> 70% * no contraindications to cardiopulmonary testing

Exclusion criteria

* documented cardiovascular disease or evidence of myocardial ischemia on the incremental exercise (VO2peak) test.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026